These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 11008125)

  • 1. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor.
    Meschler JP; Kraichely DM; Wilken GH; Howlett AC
    Biochem Pharmacol; 2000 Nov; 60(9):1315-23. PubMed ID: 11008125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of SR141716A on G-protein activation in rat brain.
    Sim-Selley LJ; Brunk LK; Selley DE
    Eur J Pharmacol; 2001 Mar; 414(2-3):135-43. PubMed ID: 11239913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.
    Hurst DP; Lynch DL; Barnett-Norris J; Hyatt SM; Seltzman HH; Zhong M; Song ZH; Nie J; Lewis D; Reggio PH
    Mol Pharmacol; 2002 Dec; 62(6):1274-87. PubMed ID: 12435794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
    Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
    J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.
    Izzo AA; Mascolo N; Pinto L; Capasso R; Capasso F
    Eur J Pharmacol; 1999 Nov; 384(1):37-42. PubMed ID: 10611417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.
    Landsman RS; Burkey TH; Consroe P; Roeske WR; Yamamura HI
    Eur J Pharmacol; 1997 Sep; 334(1):R1-2. PubMed ID: 9346339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.
    Mato S; Pazos A; Valdizán EM
    Eur J Pharmacol; 2002 May; 443(1-3):43-6. PubMed ID: 12044790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
    Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
    Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.
    Shim JY; Welsh WJ; Cartier E; Edwards JL; Howlett AC
    J Med Chem; 2002 Mar; 45(7):1447-59. PubMed ID: 11906286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.
    Ihenetu K; Molleman A; Parsons ME; Whelan CJ
    Eur J Pharmacol; 2003 Jan; 458(1-2):207-15. PubMed ID: 12498928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).
    Francisco ME; Seltzman HH; Gilliam AF; Mitchell RA; Rider SL; Pertwee RG; Stevenson LA; Thomas BF
    J Med Chem; 2002 Jun; 45(13):2708-19. PubMed ID: 12061874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
    McCollum L; Howlett AC; Mukhopadhyay S
    J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.
    Ihenetu K; Molleman A; Parsons M; Whelan C
    Eur J Pharmacol; 2003 Mar; 464(2-3):207-15. PubMed ID: 12620515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of brain cannabinoid receptors with guanine nucleotide binding protein: a radioligand binding study.
    Petitet F; Jeantaud B; Capet M; Doble A
    Biochem Pharmacol; 1997 Dec; 54(11):1267-70. PubMed ID: 9416978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
    Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
    Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
    McMahon LR
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.
    Paugh SW; Cassidy MP; He H; Milstien S; Sim-Selley LJ; Spiegel S; Selley DE
    Mol Pharmacol; 2006 Jul; 70(1):41-50. PubMed ID: 16571654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor.
    Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L
    J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.
    Nieri P; Martinotti E; Testai L; Adinolfi B; Calderone V; Breschi MC
    Eur J Pharmacol; 2003 Jan; 459(1):75-81. PubMed ID: 12505536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.